Galderma Shares Slump After FDA Turns Down Botox Rival Relfydess

1 month ago 1
ARTICLE AD BOX
Galderma Group AG shares slumped the most in more than a year after the Swiss dermatology firm said the US Food and Drug Administration had turned down its rival Botox treatment Relfydess.
Read Entire Article
  1. Homepage
  2. category-label-
  3. Galderma Shares Slump After FDA Turns Down Botox Rival Relfydess

Related

US states accuse Trump administration of ‘sham’ tariff probe

US states accuse Trump administration of ‘sham’ tariff probe...

1 hour ago 0
As ‘Spider-Man’ joins ‘The Odyssey’ in Imax, are premium movie screens worth the extra price?

As ‘Spider-Man’ joins ‘The Odyssey’ in Imax, are premium mov...

1 hour ago 0
This indicator is giving the bull market another lease on life

This indicator is giving the bull market another lease on li...

2 hours ago 0
RIGHT SIDEBAR TOP AD

Trending

1. national night out 2026
2. mike tomlin
3. gleyber torres
4. lawsuit
5. pirates vs brewers
6. portland trail blazers potential relocation
7. mitch keller
8. taylor townsend
9. juan brito
10. abimelec ortiz

Popular

Netflix investors are getting squeamish as Amazon makes inroads in the battle for streaming dominance

Netflix investors are getting squeamish as Amazon makes inro...

1 month ago 7
Some singles now expect their dates to pay for their Ubers while gas prices are so high

Some singles now expect their dates to pay for their Ubers w...

1 month ago 5
Jane Street Plans New Data Center as Compute Power Runs Scarce

Jane Street Plans New Data Center as Compute Power Runs Scar...

1 month ago 5
‘This is not a flash in the pan’ — why value stocks are beating growth by such a wide margin

‘This is not a flash in the pan’ — why value stocks are beat...

1 month ago 5
Here’s how SpaceX is pitching its IPO to everyday investors

Here’s how SpaceX is pitching its IPO to everyday investors

1 month ago 4
RIGHT SIDEBAR BOTTOM AD
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Nexus Financial News 2026. All rights are reserved